Every year, about 15 million people worldwide develop pulmonary or invasive fungal infections, which are associated with high morbidity and mortality. Early diagnosis and appropriate treatment are the major predictors of survival. Situated within the ECMM Excellence Center for Clinical Mycology at our University (one of 10 Excellence Centers worldwide reaching the highest Status of Excellence, the diamond status), our working group for translational mycology focuses on conducting cutting-edge research on clinical mycology, including fungal diagnostics, mycobiome research and pharmacology of antifungal drugs and correlation with clinical findings.


Martin Hönigl  
T: +43 316 385 31425


Our focus

  • Host pathogen interaction: immunologic markers for diagnosis and treatment stratification
  • Diagnostics Invasive fungal Infections
  • Fungi in Health and Disease: the Role of the Mycobiome
  • Fungal infections in the Intensive Care Unit: COVID associated fungal infections
  • Novel antifungals
  • Clinical Research on Antifungal Treatment and Prophylaxis



Our Network

  • We are proud of our active collaborations with leading research groups across Europe and also from other continents, who share with us the goal of advancing the field and conduct research that improves patient outcomes.

Our Projects

Posaconazole for the Prevention of COVID-19 associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study (POSACOVID)

  • Case-Control Studie zu COVID-19 assoziierter pulmonaler Aspergillpse: Fokus auf Risiko Faktoren und Mortalität, sowie den Einfluss der Prophylaxe.
  • Duration: 2020-2023
  • Funded by: MSD
  • Project partners: Prof. Gangneux, Rennes University, France and Dr. Giacobbe, University of Genoa, Italy.

Mucorales polymerase chain reaction testing in immunocompromised patients: assessing the prevalence of mucormycosis in a high-risk population (MucorPCR)

  • Evaluation of Mucorales PCR in blood and BAL samples for diagnosis of Mucormycosis.
  • Duration: 2022-2024
  • Funded by: European Confederation of Medical Mycology (Pilot) and Pfizer (full study)
  • Project partners: Prof. Kessler und Prof. Dichtl, Diagnostik- und Forschungsinstitut für Hygiene, Mikrobiologie und Umweltmedizin, Medizinische Universität Graz; Prof. Lagrou and Dr. Aert, KU Leuven, Belgium; Prof. Ibrahim, UCLA, United States

Evaluation of the IMMY Aspergillus Galactomannan Enzyme Immunoassay (Ref# AGM101) and its ability to detect Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Fluid (BALF) from patients at risk for invasive aspergillosis (IA). Method comparis

  • Prospective evaluation of a novel diagnostic ELISA test for invasive aspergillosis in serum and BALF samples.
  • Duration: 2022-2023
  • Funded by: IMMY Diagnostics
  • Project partners: Doz. Florian Prüller, Klinisches Institut für Medizinische und Chemische Labordiagnostik (KIMCL), Med Uni Graz

Characterization of patients with prolonged hospital stay for completion of parenteral antifungal therapy: Subanalysis of the ECMM Candida III Study

  • Subanalysis of the multicenter European ECMM Candida III study, where 60 centers enrolled over 600 cases with candidemia.
  • Duration: 2022-2023
  • Funded by: Mundipharma

Predicting Disease Outcomes: Role of the human respiratory and gut mycobiome

  • Evaluation of respiratory and gut Mycobiome for prognosis of adverse clinical outcomes in patients at risk for invasive fungal infections and patients with a leaky gut.
  • Duration: 2022-2024
  • Project partners: Christine Moissl-Eichinger (Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Med Uni Graz), Prof. Vanessa Stadlbauer-Köllner (Division of Gastroenterology and Hepatology, Med Uni Graz), Robert Krause und Jürgen Prattes (Division of Infectioloy, Med Uni Graz), Prof. Paul Bowyer (University of Manchester, UK)